ArticleCell death & disease2026
GIPC2 regulation of the PKM2/SREBP1 signaling axis controls adipogenic differentiation of mesenchymal stem cells.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cell (MSC) differentiation is a cornerstone of regenerative medicine with a wide range of applications in tissue engineering and translational therapies. However, the molecular mechanisms underlying MSC differentiation remain incompletely understood, preventing the full leveraging of their therapeutic potential. Central to these complex molecular networks are dynamic protein-protein interactions, with scaffolding proteins serving as master coordinators. GAIP-interacting protein C-terminus 2 (GIPC2) functions as an adaptor protein involved in mediating such interactions and may influence MSC fate by regulating differentiation-related signaling pathways. In this study, we identified GIPC2 as a novel regulator of adipogenic differentiation in human umbilical cord-derived MSCs (UC-MSCs). Mechanistically, GIPC2 interacts directly with pyruvate kinase M2 (PKM2) via its PDZ domain, promoting PKM2 nuclear translocation. In the nucleus, PKM2 facilitates the activation of sterol regulatory element-binding protein 1 (SREBP1), a transcription factor essential for lipid biosynthesis and adipocyte maturation. Our findings show that GIPC2 drives MSC adipogenic differentiation by orchestrating the PKM2-SREBP1 signaling axis. This study reveals a previously unrecognized regulatory mechanism, highlighting the pivotal role of GIPC2 at the intersection of metabolic regulation and transcriptional control. These insights not only deepen our understanding of MSC differentiation but also open new avenues for enhancing MSC-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.